Surgical oncologist Mr Myles Smith and colleagues recently had a study published into the first UK experience of cryoablation in desmoid fibromatosis. This was featured in a July edition of Clinical Radiology.
The study involved ten chosen patients and had a particular focus on technique, safety, and efficacy. Desmoid fibromatosis, is a rare type of benign tumor in the connective tissue, usually in the abdomen, arms and legs. Cyroablation is a safe and effective targeted therapy that uses intense cold to freeze and destroy abnormal areas of tissue.
The patients received thirteen procedures, between February 2019 and August 2021. Imaging was used to compare results at various stages, with results showing few adverse events and high levels of symptomatic benefit.
In summary, cryoablation for symptomatic desmoid fibromatosis is a reproducible technique with low, transient toxicity. Additionally, just one or two treatments can achieve a meaningful response. This method shows promise, but caution is needed to see how durable the response will be. If so, it may become useful addition to how we treat a challenging problem.
You can read the article here.